162 related articles for article (PubMed ID: 11320903)
1. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome.
Seipelt G; Böhme A; Koschmieder S; Hoelzer D
Ann Hematol; 2001 Mar; 80(3):170-3. PubMed ID: 11320903
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Aivado M; Schulte K; Henze L; Burger J; Finke J; Haas R
Semin Oncol; 2002 Aug; 29(4 Suppl 13):19-22. PubMed ID: 12170428
[TBL] [Abstract][Full Text] [Related]
3. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
[TBL] [Abstract][Full Text] [Related]
4. Remission of a B cell CLL-associated membranoproliferative glomerulonephritis Type I with rituximab and bendamustine.
Bartel C; Obermüller N; Rummel MJ; Geiger H; Hauser IA
Clin Nephrol; 2008 Apr; 69(4):285-9. PubMed ID: 18397703
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
8. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Weide R; Mergenthaler U; Friesenhahn V; Kleboth K; Heymanns J; Thomalla J; Köppler H
Leuk Lymphoma; 2009 Sep; 50(9):1468-74. PubMed ID: 21049589
[TBL] [Abstract][Full Text] [Related]
9. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by Rituximab.
Shvidel L; Shtalrid M; Berrebi A
Leuk Lymphoma; 2004 Jul; 45(7):1493-4. PubMed ID: 15359657
[No Abstract] [Full Text] [Related]
10. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.
Bowen DA; Call TG; Shanafelt TD; Kay NE; Schwager SM; Reinalda MS; Rabe KG; Slager SL; Zent CS
Leuk Lymphoma; 2010 Apr; 51(4):620-7. PubMed ID: 20302386
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
Gupta N; Kavuru S; Patel D; Janson D; Driscoll N; Ahmed S; Rai KR
Leukemia; 2002 Oct; 16(10):2092-5. PubMed ID: 12357362
[TBL] [Abstract][Full Text] [Related]
12. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Weide R; Heymanns J; Gores A; Köppler H
Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases.
Zaja F; Vianelli N; Sperotto A; Patriarca F; Tani M; Marin L; Tiribelli M; Candoni A; Baccarani M; Fanin R
Leuk Lymphoma; 2003 Nov; 44(11):1951-5. PubMed ID: 14738149
[TBL] [Abstract][Full Text] [Related]
15. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
Kaufman M; Limaye SA; Driscoll N; Johnson C; Caramanica A; Lebowicz Y; Patel D; Kohn N; Rai K
Leuk Lymphoma; 2009 Jun; 50(6):892-9. PubMed ID: 19391041
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
17. Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Weide R; Pandorf A; Heymanns J; Köppler H
Leuk Lymphoma; 2004 Dec; 45(12):2445-9. PubMed ID: 15621757
[TBL] [Abstract][Full Text] [Related]
18. Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.
Watanabe N; Takahashi T; Sugimoto N; Tanaka Y; Kurata M; Matsushita A; Maeda A; Nagai K; Nasu K
Int J Clin Oncol; 2005 Oct; 10(5):357-61. PubMed ID: 16247665
[TBL] [Abstract][Full Text] [Related]
19. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M
Semin Oncol; 2002 Feb; 29(1 Suppl 2):70-4. PubMed ID: 11842391
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
Swords R; Nolan A; Fay M; Quinn J; O'Donnell R; Murphy PT
Clin Lab Haematol; 2006 Feb; 28(1):57-9. PubMed ID: 16430461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]